Patient | Baseline VL | Previous ART | VL at time of VF | Observations |
---|---|---|---|---|
1 | 33 | ABC/3TC + DRV/r | 81–393 | Resuppression without switch (continued on RPV + bDRV) No drug resistance mutations. |
2 | 159 | ETV + DRV/r | 67–96 | Switch to cART (to include omeprazol). No genotyping. |
3 | 759 | ETV + DRV/r | 560–7530 | Switch to RPV+ bDRV + DTG No genotyping. |
4 | 210 | ETV + DRV/r | 191–131 | Resuppression without switch (continued on RPV + bDRV) No genotyping. |
5 | < 50 | ETV + DRV/r | 16,500 (390 five days later) | Poor adherence No switch (continued on RPV + bDRV) No genotyping. |
6 | < 50 | ETV + RAL + DRV/r | 270–1197 | Switch to ETV + DRV/r (post-switch VL of 23 copies) No drug resistance mutations |
7 | < 50 | ETV + RAL + ATV/r | 220–612 | Switch to ABC/3TC + DRV/r No drug resistance mutations |
8 | 95 | TDF/FTC + NVP | 173,000-1590 | Poor adherence No genotyping |